US FDA closes Unit 3 inspection, issues EIR

Regulatory & Legal View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹20225.00

prior close

₹20350.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.2%+0.7% vs market

Pharmaceuticals peers, median of 172sector-0.6%+0.2% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.6

15m

-1.6

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-1.2+0.7-0.6+0.2

Next day

-2.6-1.1-1.5-0.7-2.0

-4.9-2.2-2.6-1.9-3.0

-6.4-4.4-1.9-3.5-2.9

-6.2-5.5-0.7-4.3-1.9

-7.6-8.1+0.6-6.0-1.6

-4.7-5.0+0.4-2.8-1.8

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Neuland Laboratories has informed stock exchanges that the US FDA has issued an Establishment Inspection Report (EIR) for its Unit 3 manufacturing facility at Gaddapotharam, Jinnaram in Sangareddy District. The FDA has concluded the inspection, carried out from August 10 to August 14, 2026, as closed. The EIR closure generally indicates that the inspection is satisfactorily completed without outstanding compliance issues.

Likely market impact

Positive for shareholders as EIR closure removes regulatory uncertainty and confirms Unit 3 facility meets US FDA compliance standards.